Following months of negotiations with industry stakeholders, the US Food and Drug Administration (FDA) has published its proposed commitment letter for the GDUFA IV program. Announced in the Federal Register on Monday alongside details for an upcoming public meeting, the proposal introduces strategic initiatives to promote domestic manufacturing, implement a modernized meeting structure, and reduce the review cycles necessary to approve generic drugs. Reauthorization by Congress is required prior to the end of September 2027, when the current GDUFA III agreement expires, ensuring uninterrupted funding for agency operations.
Highlighting the scope of the agreement, the FDA noted in the Federal Register notice: “The proposed enhancements for GDUFA IV address many of the top priorities identified by FDA, the regulated industry, and other stakeholders. These include proposed program enhancements to stabilize fee revenue, advance approvals in fewer review cycles, improve program efficiency, enhance processes around complex data issues, and provide mechanisms to facilitate onshoring of generic drug manufacturing,” This initiative aligns with broader national goals and Executive Order 14293, which targets strengthened domestic production of essential medicines.
Proposed Statutory Adjustments and Domestic Manufacturing Incentives
Under the comprehensive FDA proposal, statutory revisions are outlined to address supply chain risks by encouraging domestic manufacturing. Starting in FY 2028, the agency proposes raising the foreign fee differential from $15,000 to $25,000 for foreign Active Pharmaceutical Ingredient (API), Finished Dosage Form (FDF), and Contract Manufacturing Organization (CMO) facilities. Agency discussions noted that foreign fees under the current fee structure have remained unchanged since FY 2013, though industry representatives expressed concern that higher fees might prompt companies to exit the US market.
Another key element of the FDA proposal involves a statutory amendment waiving application fees for the first three years for companies that establish manufacturing operations to produce finished generic drugs or APIs domestically. Additionally, existing US generic API and FDF facilities without a recent inspection history can request an inspection 24 months prior to a planned Drug Master File (DMF) or Abbreviated New Drug Application (ANDA) submission.
New Meeting Pathways and Administrative Enhancements
To facilitate clearer communication, the agreement establishes four new meeting categories between industry applicants and the agency:
A Type 30 meeting permits applicants to seek clarification regarding prior agency interactions or guidance changes affecting ongoing ANDA submissions. A Type 60 meeting provides targeted follow-up on previously discussed topics. A Type 90 meeting allows applicants to introduce a single new issue. Finally, a Type 120 meeting is structured to address complex, multi-topic matters requiring extensive coordination.
Efficiency Measures and Database Expansion
Administrative processes will be further streamlined under the framework. Applicants will utilize a pre-assigned ANDA number when submitting controlled correspondence, eliminating the need to re-submit prior documentation. Where complex data issues arise, the agency may set a new goal date six months beyond the original, offering follow-up meetings if the revised date is missed. Periodic updates to the Inactive Ingredient Database (IID) will continue quarterly, adding ingredients identified in labeling approved on or after October 1, 2027. Furthermore, the agency intends to build a public Maximum Daily Dose (MDD) database containing at least 500 reference listed drug values by FY 2028 while seeking public input on its utility.
The framework also expands eligibility for DMF prior assessments to include complex APIs and supplements introducing new US API sources. Separately, drug, regulatory, and laboratory animal testing organizations continue to request agency flexibility regarding when animal testing is required versus alternative safety data for cancer therapies. Adjustments to the overall fee structure aim to stabilize revenue ahead of the expiration of GDUFA III in September 2027, laying the groundwork for the GDUFA IV program to maintain continuity across regulatory pathways.
